Safety
ADVERSE EVENT
Median duration of exposure to study treatment was 44.9 (range, 20.1–101.6) weeks for asciminib and 3.1 (range, 1.3–29.0) weeks for bosutinib. Overall, 10 (76.9%) patients in the asciminib group, and 3 (100.0%) patients in the bosutinib group experienced at least 1 AE (any grade) during the study (Table Adverse events occurring in ≥2 patients
Grade ≥ 3 clinical laboratory or electrocardiogram abnormalities observed with asciminib included decreased neutrophils (23.1%), decreased platelets (1.7%), decreased leukocytes (1.7%), and ECG QT prolongation (1.7%), and only increased ALT (33.3%) was observed with bosutinib.